US 12,297,262 B2
RGMC-selective inhibitors and use thereof
Samantha Nicholls, Arlington, MA (US); Adriana Donovan, West Roxbury, MA (US); Meghan McDonald, London (GB); Abhishek Datta, Boston, MA (US); Allan Capili, Somerville, MA (US); Kevin B. Dagbay, Brighton, MA (US); Lorena Lerner, Newton, MA (US); Leonard Ira Zon, Wellesley, MA (US); Kevin Schutz, Lebanon, NH (US); John Bukowski, Lebanon, NH (US); and Justin W. Jackson, Cambridge, MA (US)
Assigned to Scholar Rock, Inc., Cambridge, MA (US)
Appl. No. 17/285,952
Filed by Scholar Rock, Inc., Cambridge, MA (US)
PCT Filed Oct. 23, 2019, PCT No. PCT/US2019/057687
§ 371(c)(1), (2) Date Apr. 16, 2021,
PCT Pub. No. WO2020/086736, PCT Pub. Date Apr. 30, 2020.
Claims priority of provisional application 62/749,469, filed on Oct. 23, 2018.
Prior Publication US 2021/0380669 A1, Dec. 9, 2021
Int. Cl. C07K 16/18 (2006.01); A61P 7/06 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 7/06 (2018.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 35 Claims
 
1. An antibody or antigen-binding fragment thereof that binds to Repulsive Guidance Molecule C (RGMc) comprising three heavy chain complementarity determining regions (H-CDRs), H-CDR1, H-CDR2, and H-CDR3, and three light chain CDRs, L-CDR1, L-CDR2, and L-CDR3, wherein:
i) the H-CDR1 comprises the amino sequence of SEQ ID NO: 30, the H-CDR2 comprises the amino sequence of SEQ ID NO: 31, the H-CDR3 comprises the amino sequence of SEQ ID NO: 32, the L-CDR1 comprises the amino sequence of SEQ ID NO: 33, the L-CDR2 comprises the amino sequence of SEQ ID NO: 34, and the L-CDR3 comprises the amino sequence of SEQ ID NO: 35;
ii) the H-CDR1 comprises the amino sequence of SEQ ID NO: 6, the H-CDR2 comprises the amino sequence of SEQ ID NO: 7, the H-CDR3 comprises the amino sequence of SEQ ID NO: 8, the L-CDR1 comprises the amino sequence of SEQ ID NO: 9, the L-CDR2 comprises the amino sequence of SEQ ID NO: 10, and the L-CDR3 comprises the amino sequence of SEQ ID NO: 11;
iii) the H-CDR1 comprises the amino sequence of SEQ ID NO: 14, the H-CDR2 comprises the amino sequence of SEQ ID NO: 15, the H-CDR3 comprises the amino sequence of SEQ ID NO: 16, the L-CDR1 comprises the amino sequence of SEQ ID NO: 17, the L-CDR2 comprises the amino sequence of SEQ ID NO: 18, and the L-CDR3 comprises the amino sequence of SEQ ID NO: 19;
iv) the H-CDR1 comprises the amino sequence of SEQ ID NO: 22, the H-CDR2 comprises the amino sequence of SEQ ID NO: 23, the H-CDR3 comprises the amino sequence of SEQ ID NO: 24, the L-CDR1 comprises the amino sequence of SEQ ID NO: 25, the L-CDR2 comprises the amino sequence of SEQ ID NO: 26, and the L-CDR3 comprises the amino sequence of SEQ ID NO: 27; or
v) the H-CDR1 comprises the amino sequence of SEQ ID NO: 38, the H-CDR2 comprises the amino sequence of SEQ ID NO: 39, the H-CDR3 comprises the amino sequence of SEQ ID NO: 40, the L-CDR1 comprises the amino sequence of SEQ ID NO: 41, the L-CDR2 comprises the amino sequence of SEQ ID NO: 42, and the L-CDR3 comprises the amino sequence of SEQ ID NO: 43; and
wherein the antibody or antigen-binding fragment is an RGMc-selective inhibitor.